J&J Agrees to $5.5B Talc Settlement
The story in brief
Johnson & Johnson has reached a $5.5 billion settlement with ovarian cancer claimants in talc lawsuits, which must be accepted by 95% of claimants to finalize. The deal covers 99.75% of remaining talc claims, with J&J denying its products caused cancer. The litigation resumed in March 2025 after a three-year pause, following a recent court victory that cast doubt on plaintiffs' ability to prove causation.